株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

風疹:パイプライン製品の分析

Rubella (German Measles) - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 271825
出版日 ページ情報 英文 45 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.78円で換算しております。
Back to Top
風疹:パイプライン製品の分析 Rubella (German Measles) - Pipeline Review, H2 2016
出版日: 2016年11月16日 ページ情報: 英文 45 Pages
概要

風疹は、三日ばしかとしても知られる、急性の接触伝染性ウイルス感染症です。風疹ウイルスは、感染者のくしゃみや咳の飛沫によって伝染します。発熱、頭痛、鼻づまりや鼻水、炎症、眼の充血、関節痛、頭蓋底・頸背部・耳介後部のリンパ節腫大などの症状があります。

当レポートでは、風疹に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

風疹の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

風疹:企業で開発中の治療薬

風疹:大学/機関で研究中の治療薬

風疹:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

風疹:企業で開発中の製品

風疹:大学/機関で研究中の製品

風疹の治療薬開発に従事している企業

  • Beijing Minhai Biotechnology Co., Ltd
  • Beijing Tiantan Biological Products Co., Ltd.
  • Biological E. Limited
  • China National Pharmaceutical Group Corporation
  • 第一三共
  • GlaxoSmithKline Plc
  • Prometheon Pharma, LLC
  • Sinovac Biotech Ltd.
  • Zydus Cadila Healthcare Limited

風疹:治療薬の評価

  • 単剤製品
  • 併用製品
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

風疹:最近のパイプライン動向

風疹:休止中のプロジェクト

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8643IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rubella (German Measles) - Pipeline Review, H2 2016, provides an overview of the Rubella (German Measles) (Infectious Disease) pipeline landscape.

Rubella also known as the German measles is an acute, contagious viral infection. The rubella virus is transmitted by airborne droplets when infected people sneeze or cough. Symptoms include fever, headache, stuffy or runny nose, inflamed, red eyes, aching joints and enlarged, tender lymph nodes at the base of the skull, the back of the neck and behind the ears.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rubella (German Measles) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Rubella (German Measles) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rubella (German Measles) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rubella (German Measles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 2, 1, 2, 1 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.Rubella (German Measles).

Rubella (German Measles) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rubella (German Measles) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Rubella (German Measles) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rubella (German Measles) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rubella (German Measles) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rubella (German Measles) (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rubella (German Measles) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rubella (German Measles) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Rubella (German Measles) Overview
  • Therapeutics Development
    • Pipeline Products for Rubella (German Measles) - Overview
    • Pipeline Products for Rubella (German Measles) - Comparative Analysis
  • Rubella (German Measles) - Therapeutics under Development by Companies
  • Rubella (German Measles) - Therapeutics under Investigation by Universities/Institutes
  • Rubella (German Measles) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Rubella (German Measles) - Products under Development by Companies
  • Rubella (German Measles) - Products under Investigation by Universities/Institutes
  • Rubella (German Measles) - Companies Involved in Therapeutics Development
    • Beijing Minhai Biotechnology Co., Ltd
    • Beijing Tiantan Biological Products Co., Ltd.
    • Biological E. Limited
    • Daiichi Sankyo Company, Limited
    • GlaxoSmithKline Plc
    • Indian Immunologicals Limited
    • Prometheon Pharma, LLC
    • Sinovac Biotech Ltd.
    • Zydus Cadila Healthcare Limited
  • Rubella (German Measles) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (measles + mumps + rubella + varicella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + mumps + rubella + varicella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + mumps + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + mumps + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + mumps + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + rubella + varicella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rubella vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VN-0102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Rubella (German Measles) - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Rubella (German Measles), H2 2016
  • Number of Products under Development for Rubella (German Measles) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Rubella (German Measles) - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016
  • Rubella (German Measles) - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2016
  • Rubella (German Measles) - Pipeline by Biological E. Limited, H2 2016
  • Rubella (German Measles) - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Rubella (German Measles) - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Rubella (German Measles) - Pipeline by Indian Immunologicals Limited, H2 2016
  • Rubella (German Measles) - Pipeline by Prometheon Pharma, LLC, H2 2016
  • Rubella (German Measles) - Pipeline by Sinovac Biotech Ltd., H2 2016
  • Rubella (German Measles) - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Rubella (German Measles) - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Rubella (German Measles), H2 2016
  • Number of Products under Development for Rubella (German Measles) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top